You have accessJournal of UrologyCME1 Apr 2023LBA01-18 COMPARISON OF MIRABEGRON AND VIBEGRON FOR CLINICAL EFFICACY AND SAFETY IN FEMALE PATIENTS WITH OVERACTIVE BLADDER: A MULTICENTER, PROSPECTIVE RANDOMIZED CROSSOVER TRIAL Naoki Wada, Noriyuki Abe, Kotona Miyauchi, Shin Kobayashi, Miyu Ohtani, Ryoken Tsunekawa, Masaya Nagabuchi, Shun Morisita, Hidehiro Kakizaki, Mitsuhiro Mizunaga, Teppei Ohyama, Satoshi Yamaguchi, Hiromitsu Iuchi, Tsuyoshi Noda, Yuji Saga, Tadasu Motoya, Norihiro Kawakami, Masayuki Nishihara, and Atsushi Numata Naoki WadaNaoki Wada More articles by this author , Noriyuki AbeNoriyuki Abe More articles by this author , Kotona MiyauchiKotona Miyauchi More articles by this author , Shin KobayashiShin Kobayashi More articles by this author , Miyu OhtaniMiyu Ohtani More articles by this author , Ryoken TsunekawaRyoken Tsunekawa More articles by this author , Masaya NagabuchiMasaya Nagabuchi More articles by this author , Shun MorisitaShun Morisita More articles by this author , Hidehiro KakizakiHidehiro Kakizaki More articles by this author , Mitsuhiro MizunagaMitsuhiro Mizunaga More articles by this author , Teppei OhyamaTeppei Ohyama More articles by this author , Satoshi YamaguchiSatoshi Yamaguchi More articles by this author , Hiromitsu IuchiHiromitsu Iuchi More articles by this author , Tsuyoshi NodaTsuyoshi Noda More articles by this author , Yuji SagaYuji Saga More articles by this author , Tadasu MotoyaTadasu Motoya More articles by this author , Norihiro KawakamiNorihiro Kawakami More articles by this author , Masayuki NishiharaMasayuki Nishihara More articles by this author , and Atsushi NumataAtsushi Numata More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003360.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Mirabegron is approved as the first β3-adrenoceptor agonist for overactive bladder (OAB). Vibegron is a secondly approved β3-adrenoceptor agonist for OAB. The efficacy and safety of vibegron compared with mirabegron are unknown because of the lack of head-to-head comparative study. In this trial, we compared the efficacy and safety of mirabegron and vibegron in female OAB patients. METHODS: We conducted a multicenter, prospective randomized crossover study. We enrolled female OAB patients aged ≥50 years, who had been treatment naive for OAB. The patients were assigned to Group MV or VM. Group MV patients were administered mirabegron (50 mg per day) for 8 weeks, followed by vibegron (50 mg per day) for 8 weeks. This order of drug administration was reversed in Group VM. There was no wash out period prior to crossover. At baseline, 8th week and 16th week, overactive bladder symptoms score (OABSS) consisting of daytime frequency, nighttime frequency, urgency and urgency incontinence, and frequency-volume charts (FVC) for 3 days were obtained in each patient. The primary end point is the change of OABSS from the baseline. After the completion of the trial, each patient was asked which drug was preferable. RESULTS: A total of 80 patients enrolled in this trial (39 in Group MV and 41 in Group VM). At 8th and 16th week, 31 and 28 patients in Group MV and 33 and 29 in Group VM continued to receive the treatment. Three patients withdrew the treatment due to adverse events including dizziness in one during mirabegron, constipation and elevated postvoid residual (PVR) in one each during vibegron. The change of PVR was not significantly different during mirabegron (3.1±26.5 ml) and vibegron (7.9±9.8 ml) (p=0.43). Both mirabegron and vibegron significantly improved OABSS (-4.3±3.4 vs -5.3±3.4), daytime (-1.0±2.0 vs -1.6±2.0) and nighttime frequency (-0.3±1.0 vs -0.4±0.9) per day, mean (35±47 vs 42±47 ml) and maximum voided volume (55±96 vs 57±109 ml). There was no significant difference in the changes of these parameters between mirabegron and vibegron. After the completion of the trial, 15 and 33 of 57 patients preferred mirabegron (26%) and vibegron (58%), respectively. The other 9 patients (16%) had no preference. The change of urgency incontinence score of OABSS during vibegron was better in patients who preferred vibegron to mirabegron (-2.1±1.6 vs -1.1±1.4, p<0.05). CONCLUSIONS: The efficacy of mirabegron and vibegron for female OAB patients is similar. The patients’ preference for vibegron could be depending on the better efficacy for urgency incontinence. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1184 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Naoki Wada More articles by this author Noriyuki Abe More articles by this author Kotona Miyauchi More articles by this author Shin Kobayashi More articles by this author Miyu Ohtani More articles by this author Ryoken Tsunekawa More articles by this author Masaya Nagabuchi More articles by this author Shun Morisita More articles by this author Hidehiro Kakizaki More articles by this author Mitsuhiro Mizunaga More articles by this author Teppei Ohyama More articles by this author Satoshi Yamaguchi More articles by this author Hiromitsu Iuchi More articles by this author Tsuyoshi Noda More articles by this author Yuji Saga More articles by this author Tadasu Motoya More articles by this author Norihiro Kawakami More articles by this author Masayuki Nishihara More articles by this author Atsushi Numata More articles by this author Expand All Advertisement PDF downloadLoading ...